Back to top

Keros Therapeutics to receive $20M elritercept milestone payment from Takeda

Keros Therapeutics (KROS) announced that it will receive a $20M development milestone payment under the terms of the license agreement of elriterce...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Keros Therapeutics, Inc. (KROS)

Takeda Pharmaceutical Co. (TAK)